News for AstraZeneca PLC (ZEG.DE)

AstraZeneca PLC (NASDAQ:AZN) is included among the Top 10 Safest Dividend Stocks in the UK. AstraZeneca PLC (NASDAQ:AZN) is well-positioned to handle upcoming patent expirations, thanks to a robust pipeline of drugs in development. By the close of the first quarter, the company had gained approval or label updates for roughly 13 treatments. Two of […]

Today's Research Daily features new research reports on 16 major stocks, including NVIDIA, Netflix, and Goldman Sachs, as well as a micro-cap stock, AMREP.

AstraZeneca (AZN) is set to enhance its environmental efforts with a significant development for its Trixeo Aerosphere treatment, used for chronic obstructive p

Key Highlights: AstraZeneca's gefurulimab shows promising results in a Phase 3 study for generalized myasthenia gravis. Wall Street analysts forecast potenti

AstraZeneca's (AZN) recent Phase III trial has yielded positive outcomes for gefurulimab, a treatment aimed at adults dealing with anti-acetylcholine receptor a

Key Highlights: AstraZeneca plans a $50 billion U.S. investment by 2030, focusing on expanding its manufacturing capabilities. Average analyst price targ

AstraZeneca PLC (NASDAQ:AZN), a global biopharmaceutical company headquartered in Cambridge, UK, operates in over 130 countries with more than 80,000 employees.

Should upset the anti vaxxer morons

Summary AstraZeneca PLC (AZN) announced positive results from the final overall survival analysis of the FLAURA2 Phase III trial, revealing that TAGRISSO® (osi

The FLAURA2 Phase III trial's final analysis has revealed that AstraZeneca's (AZN) Tagrisso, when combined with pemetrexed and platinum-based chemotherapy, sign

AstraZeneca (AZN) revealed promising outcomes from the final overall survival analysis of the Phase III FLAURA2 trial. This study investigated the efficacy of c

AstraZeneca PLC (NASDAQ:AZN) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. AstraZeneca PLC (NASDAQ:AZN) has a strong lineup of drugs in development, which should help it navigate upcoming patent expirations. By the end of the first quarter, it had secured around 13 drug approvals or label updates. Among its most promising […]

The US pharmaceutical industry has undergone notable shifts in recent years, influenced by factors such as the COVID-19 pandemic, expanded collaborations across the value chain, and ongoing changes in...

Key Takeaways: Enhertu, a collaborative drug by AstraZeneca and Daiichi Sankyo, receives breakthrough therapy designation in the U.S. Wall Street analyst

AstraZeneca (AZN) has announced a significant development regarding its drug, Enhertu. The combination of Enhertu with pertuzumab has received Breakthrough Ther

Key Highlights: AstraZeneca's experimental treatment anselamimab did not achieve its primary goals in the latest trial. Analyst consensus sets the average ta

AstraZeneca PLC (NASDAQ:AZN) is one of Goldman Sachs’ top healthcare stock picks. On July 4, the company secured regulatory approval for Imfinzi (durvalumab). The approval is for the use of the drug for the treatment of muscle-invasive bladder cancer (MIBC). The regulatory approval by the European Commission follows a positive opinion by the Committee for […]

AstraZeneca's phase 3 trial reveals promising results for hypertension treatment with baxdrostat. Analysts predict significant stock price growth, with

AstraZeneca (AZN) experienced a 1% increase in its stock following positive outcomes from its BaxHTN clinical trial. The company announced that the trial succes